The table below shows Foghorn Therapeutics Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q3 2025
Q2 2025
Q1 2025
Q3 2024
Q2 2024
Revenue
$3.27M
$8.15M
$7.56M
$5.95M
$7.81M
$6.89M
Cost of revenue
-
-
-
-
-
-
Gross profit
-
-
-
-
-
-
R&D
$18.26M
$20.00M
$21.79M
$21.63M
$24.69M
$23.80M
SG&A
FHTX annual revenue (10-K history)
Foghorn Therapeutics Inc. reported annual revenue of $30.91M for fiscal year 2025. That is up 36.8% from $22.60M in fiscal 2024. Over the 6 fiscal years shown, annual revenue grew from $430.00K (FY 2020) to $30.91M. Figures come from the company's audited annual reports as filed with the SEC.